Form 4: Teva Pharmaceutical Industries: Chief Accounting Officer Reports Share Disposals Following Vesting of Restricted Share Units
SEC Form 4 Filing
Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the disposal of ordinary shares following the vesting of restricted share units.
Summary
- On March 3, 2025, Amir Weiss, the Chief Accounting Officer of Teva Pharmaceutical Industries, reported transactions involving ordinary shares.
- These transactions involved the vesting of 5,179 restricted share units, each representing a contingent right to receive one ordinary share or its cash value.
- Following the vesting, Mr. Weiss disposed of 10,358 ordinary shares.
- After the reported transactions, Mr. Weiss directly owns 10,359 ordinary shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an executive, with no inherent positive or negative sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in beneficial ownership.
Key Dates
| Date | Description |
|---|---|
| March 3, 2023 | Restricted share units were granted. |
| March 3, 2024 | 5,179 restricted share units vested. |
| March 3, 2025 | Earliest transaction date; 5,179 restricted share units vested; 10,358 ordinary shares disposed of. |
| March 3, 2026 | 5,179 restricted share units will vest. |
| March 3, 2027 | 5,180 restricted share units will vest. |
| March 5, 2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.